Share Email Print
cover

Proceedings Paper

Local hyperthermia for the treatment of diseases of the prostate
Author(s): Ciro Servadio
Format Member Price Non-Member Price
PDF $14.40 $18.00
cover GOOD NEWS! Your organization subscribes to the SPIE Digital Library. You may be able to download this paper for free. Check Access

Paper Abstract

During the past decade, the authors have been involved extensively in the use of local Microwave Hyperthermia (915 MHz) to the prostate, delivered transrectally. The initial purpose was to use local heat (41 degree(s)-44 degree(s)C) in order to treat cancer of the prostate which is a very common problem in western society, responsible for considerable morbidity and mortality. At a later stage, benign prostatic enlargement and chronic prostatitis were included in the clinical studies. A special apparatus was developed for this purpose known as the Prostathermer (Biodan Co.). Treatment was found to be safe, easy to perform, well-tolerated by patients, and effective in bringing about relief in obstructive and irritative symptoms of prostatism, with local regression in cancer patients. Such has been the experience in several hundreds of patients and thousands of treatment with years of follow-up. Similar experience was shared by several other investigators in several countries. Local hyperthermia to the prostate has opened new horizons for urological clinical work and research. For the moment, it should be regarded as a therapeutic option, both by itself and also in conjunction with other forms of treatment for the various pathologies of the prostate.

Paper Details

Date Published: 1 July 1991
PDF: 6 pages
Proc. SPIE 1421, Lasers in Urology, Laparoscopy, and General Surgery, (1 July 1991); doi: 10.1117/12.43898
Show Author Affiliations
Ciro Servadio, Beilinson Medical Ctr. and Sackler School of Medicine/Tel-Av (Israel)


Published in SPIE Proceedings Vol. 1421:
Lasers in Urology, Laparoscopy, and General Surgery
Graham M. Watson; Rudolf W. Steiner; Joseph J. Pietrafitta, Editor(s)

© SPIE. Terms of Use
Back to Top